Barcelona

Scientific Programme

The Academy day will have a range of educational symposia covering many different topics and will include interactive sessions. The main scientific programme will include new topics and new ISBT speakers. 

Programme subject to change.

Programme per day

09.00-11.00Topic / Speaker
09.00-09.15Introducción
J. Cárdenas & E. Muñiz-Diaz
09.15-09.45Un enfoque práctico y realista de la implementación de las  “Directrices de buenas prácticas” en los centros de transfusión
J. Arroyo 
09.45-10.15Estado actual del cribado del virus de la hepatitis E
S. Sauleda 
10.15 - 10.30Discusión 
10.30-11.00Coffee break
11.00-13.30Topic / Speakers
11.00-11.30Contaminación bacteriana de los concentrados de plaquetas: ¿un reto pendiente?
M. Lozano
11.30-12.00Interferencias en las pruebas de compatibilidad generadas por los nuevos tratamientos con anticuerpos monoclonales.
Posibles soluciones
E. Muñiz-Diaz
12.00-12.30Anemia, transfusión y mortalidad en el enfermo cardiaco
P. Cepas
12.30-13.00Obtención y producción de CAR-T
D. Benitez
13.00-13.30Discusión
13.30Lunch break
14.30-16.30Topic / Speaker
14.30-15.00Papel, objetivos y recursos de la I+D+i en Centros de Transfusión
J. García
15.00-15.30Aspectos éticos relacionados con la donación de sangre
H. Gonçalves / M. Jose Gomes
15.30-16.00Grupo Cooperativo Iberoamericano de Medicina Transfusional (GCIAMT)
S. Kuperman
16.00-16.25Discusión
16.25-16.30Conclusiones
J. Cárdenas & E. Muñiz-Diaz
08.30-10.00Aspects to be considered to connect with the donor community
08.30-09.00What motivates or hinders donors to give blood?
E. Merz (Netherlands)
09.00-09.30Profile of non-donors, occasional donors and regular donors
T. Daruma (Malaysia)
09.30-10.00Bringing back lapsed donors
J. Leon (Australia)
08.30-10.00Transfusion protocols in trauma and massive bleeding
08.30-09.00Pathophysiology of trauma
M. Reade (Australia)
09.00-09.30Evidence for blood product use in trauma and massive bleeding
K. Gunn (New Zealand)
09.30-10.00Mass casualty and emergency preparedness
H. Doughty (United Kingdom)
10.30-11.00Coffee break
10.30-12.00Advancing blood systems globally
10.30-11.00The WHO vision for advancing blood systems
J. Epstein (USA)
11.00-11.20Between ideals and reality
S. Owusu-Ofori (Ghana)
11.20-11.40Strategizing WHO priorities and actions
D. Teo (Singapore)
11.40-12.00Discussion
10.30-12.00Solutions to unmet transfusion needs
10.30-11.00Platelet refractoriness: options for the best match
P. Hoglund (Sweden)
11.00-11.30Ins-and outs of cold-stored platelets and their clinical use
T. Apelseth (Norway)
11.30-12.00Antigen-modified cultured red blood cells: how to produce and to use
M. Meinders (United Kingdom)
12.30-13.30Lunch and Satellite Symposia
13.30-15.00How to conduct research studies
13.30-14.00Pitfalls in design and analysis in clinical studies
L. van de Watering (The Netherlands)
14.00-14.30Blood loss around delivery: how to measure and to improve the care in a center in Ethiopia?
A. Tura (Ethiopia)
14.30-15.00Human T-Cell Lymphotropic Virus Type I and II (HTLV I/II) Seroprevalence Among Volunteer Blood Donors In The National Blood Centre, Kuala Lumpur (NBCKL): Protocol Development Through I TRY IT Programme.
N. Jamaludin (Malaysia)
13.30-15.00New laboratory techniques used in the transfusion laboratory to improve clinical advice and product selection
13.30-14.00Next-generation-sequencing-based HLA typing: how is it done and what did it bring?
M. José Herrero (Spain)
14.00-14.30An overview on digital-droplet PCR for precise fetal typing and the use of NGS-based red blood cell typing
H. O'Brien (Australia)
14.30-15.00The collaboration between laboratory and the clinic to provide typed red blood cells in autoimmune haemolytic anaemia
M. Raos (Croatia)
15.00-15.30Coffee break
15.30-17.00All about the ISBT activities
15.30-15.50Update on ISBT's educational activities
E.Herczenik (The Netherlands)
15.50-16.10Why ISBT? What's in it for a YP?
T. Hutchinson (USA)
16.10-16.30What and how to achieve to make molecular database accessible
C. Gassner (Switzerland)
16.30-16.50Clinical Transfusion WP outreach activities
C. So-Osman (The Netherlands)
15.30-17.00SCD and molecular techniques in treatment and transfusion policy
15.30-16.00The clinical epidemiology of SCD in Africa
S. Uyoga (Kenya)
16.00-16.30Current understanding of the molecular pathophysiology of SCD
H. Al Balushi (Oman)
16.30-17.00Gene therapy for hemoglobinopathies: progress and future challengesc
W. El Nemer (France)
08.30-10.00Donors and Donation
08.30-09.00An update on the International Rare Donor Panel (IRDP); whats in the future? 
N. Thornton (United Kingdom)
09.00-10.00Selected abstracts
08.30-10.00Immunobiology 
08.30-09.00Climate change and its affects on the Migration of Arboviruses: Impact on Blood Safety
J. Semenza (Sweden)
09.00-10.00Selected abstracts
08.30-10.00Clinical
08.30-09.00Outcomes for clinical trials in transfusion: Is the bleeding score necessary?
Terry Gernsheimer (USA)
09.00-10.00Selected abstracts
08.30-10.00Cellular Therapies
08.30-10.00Selected abstracts
08.30-10.00Working Party session: Update of TTID Working Party Activities
08.30-08.45Overview of Working Party
B. Custer (USA)
08.45-09.10SRAP Subgroup
W. Steele (USA)
09.10-09.35Parasites Subgroup
E. Bloch (USA)
09.35-10.00Bacteria Subgroup
S. Ramirez (Canada)
08.30-10.00Working Party session: Computer System Guideline Challenges
08.30-09.00Computer System Infrastructure Qualifications – Expanding an Existing Validation Guideline
J. Georgsen (Denmark)
09.00-09.30Complexities and Ramifications of a Traceability Guideline
M. Breard (USA)
09.30-10.00Discussion
08.30-10.00Peer Review Workshop
M. Lozano & D. Marks
10.00-10.30Coffee break

 

 

10.30-12.00Plenary Session I: Post-partum hemorrhage: How can it be reduced?
10.30-11.00Management of post-partum hemorrhage
R. Collis (United Kingdom)
11.00-11.30Post partum hemorrhage in Africa
R. Larsen-Reindorf (Ghana) 
11.30-12.00A multimedia approach to post partum haemorrhage
B. Hunt / M. Keep (United Kingdom)
12.00-14.00Lunch break and Satellite Symposia
14.00-15.30Donors and Donation
14.00-14.30Iron monitoring in whole blood donors: seeking an optimal balance between donor availability and health
K. van den Hurk (The Netherlands)
14.30-15.30Selected abstracts
14.00-15.30Blood Products
14.00-14.30Making whole blood for trauma available again
P. Young (USA)
14.30-15.00Blood products exert inflammatory insults; are there consequences? 
F. Noizat-Pirenne (France)
15.00-15.30Selected abstracts
14.00-15.30TTID Abstract session
14.00-15.30Management and Organisation
14.00-14.30Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference
M. Mueller (Germany)
14.30-15.30Selected abstracts
14.00-15.30Young Investigators Session
15.30-16.00 Break, exhibition and poster display

 

16.00-17.30Clinical (Joint ISBT / AABB)
16.00-16.30Epidemiology and National Trends in Pediatric Transfusion: Where do we stand?
R. Goel (USA)
16.30-17.00Transfusion and Anemia Expert Initiative - Control/Avoidance of Bleeding (TAXI-CAB) 
M. Nellis (Israel)
17.00-17.30Anemia at Pediatric Intensive Care Unit Discharge
P. Demaret (France)
16.00-17.30Blood products: A Focus on Platelets
16.00-16.30Alternative methods of platelet storage and pathogen reduction
T. Jimenez-Marco (Spain)
16.30-17.00Platelets refrigerated and cryopreserved. A current alternative, valid and useful
J. Rivera (Spain)
17.00-17.30Selected abstracts
16.00-17.30Immunobiology 
16.00-16.30Complement in transfusion medicine
M. Scully (United Kingdom)
16.30-17.30Selected abstracts
16.00-17.30Immunology
16.00-16.30Blood group antigens in the genomicera
C. Hyland (Australia)
16.30-17.30Selected abstracts
16.00-17.30Management and Organisation
16.00-16.30Full electronic traceability: From collection to transfusion
M. Angel Vesga Carasa (Spain)
16.30-17.30Selected abstracts
16.00-17.30Update on Rh Disease and the WIRhE Initiative
16.00-16.20The global epidemiology of Rh disease and the rationale for the WIRhE initiative
B. Stotler (USA)
16.20-16.40Current issues in Rh disease: The perspective from Nigeria
A. Okolo (Nigeria)
16.40-17.00Improving Rh disease prevention in rural Pakistan: A scientific study
L. Pell (Canada)
17.00-17.20Rh disease prevention: The European perspective
C. Toly Ndour (France)
17.20-17.30Discussion
16.00-17.30WP session IIII: Donors and Donation
16.00-16.30Periodontitis in blood donors
C. Damgaard (Denmark)
16.30-17.00Ethics in relation to plasma donors
F. Rossi (France)
17.00-17.30The WHO viewpoint on donor ethics
Y. Abdella (Egypt)
20.00-23.00Speakers Dinner
08.30-10.00Donors and Donation
08.30-09.00Lymphopenia in frequent Blood donors
M. Rahmani (Canada)
09.00-10.00Selected abstracts
08.30-10.00Blood products
08.30-09.00In vitro RBC production for diagnostic purposes
N. Nogués (Spain)
09.00-10.00Selected abstracts
08.30-10.00Blood safety
08.30-09.00Bacterial sepsis in transfusion recipients despite secondary mitigation strategies
M. Prax (Germany)
09.00-10.00Selected abstracts
08.30-10.00Immunology
08.30-09.00New insights into Fetal/Neonatal Alloimmune Thrombocytopenia
N. Cooper (Germany)
09.00-10.00Selected abstracts
08.30-10.00Clinical
08.30-09.00Management of massive haemorrhage
A.M. Gómez-Caro (Spain)
09.00-10.00Selected abstracts
08.30-10.00Working Party Global blood safety 
08.30-09.00Production of virus-inactivated S/D-cryo in Egypt - Practical experience and impact on patient's health
M. El-Ekiaby (Egypt)
09.00-09.30Thailand experience all the way from cryo, dry-heated cryo, and domestic industrial Factor VIII concentrate production
U. Charoonruangrit (Thailand)
09.30-10.00A global perspective on availability of safe plasma products for treatment of bleeding disorders: filling the supply and safety gaps
Y. Maryuningsih (Indonesia)
10.00-10.30 Break, exhibition and poster display

 

10.30-12.00Plenary Session II: The Gut Microbiome in transfusion medicine
10.30-11.00Converting RBC units to group O with gut-derived bacteria
S. Withers (Canada)
11.00-11.30How transfusion alters the gut microbiome and its implications
H.A. Goubran Messiha (Canada)
11.30-12.00The microbiome of healthy blood donors and its role in potential transfusion reactions
B. Lelouvier (France)
12.00-14.00Lunch break and Satellite Symposia
13.00-13.45ISBT General Assembly
14.00-15.30Blood products
14.00-14.30IVIg: Are replacements available?
A. Lazarus (Canada)
14.30-15.30Selected abstracts
14.00-15.30Blood safety
14.00-14.30Blood groups and the risk of thrombosis
D. Kenny (Ireland)
14.30-15.30Selected abstracts
14.00-15.30Immunology
14.00-14.30Microparticles in transfusion medicine
E. Boilard (Canada)
14.30-15.30Selected abstracts
14.00-15.30Working Party Session: Rare Donors
14.00-14.30Clinical Dilemmas in the Allocation of Rare Blood
V. Yahalom (Israel)
14.30-15.00Ethical Dilemmas in the Allocation of Rare Blood
P. Flanagan (New Zealand)
15.00-15.30Provision of Rare Blood: experiences from the Frontlines 
N. Thornton (United Kingdom)
14.00-15.30Working Party Session: Haemovigilance 
14.00-14.10Haemovigilance at the crossroads
J. Wiersum (The Netherlands)
14.10-14.30Lessons learned from promoting data harmonisation and how we detect signals across plasma-derived medicines
E. Van Puijenbroek (The Netherlands)
14.30-14.50Big Data and linking routine databases
S. Vossoughi (USA)
14.50-15.10Update on collaborative hemovigilance activities in Latin American countries
E. Muñiz-Diaz (Spain)
15.10-15.30Discussion
K. Land, moderator (USA)
14.00-15.30Transfusion Practitioner session
14.00-14.30Novice to expert trajectory – skills, attributes, behaviours and aptitude, competency framework
A. Miller (United Kingdom)
14.30-15.00What technology will help or create challenges for the TP
M. Rowley (United Kingdom)
15.00-15.30Extending the TP role through research and publications
E. Wood (Australia)
15.30-16.00Coffee break, exhibition and poster display
16.00-17.30Donors and Donation
16.00-16.30Improving blood delivery to disaster-hit areas
X. Song (United Kingdom)
16.30-17.30Selected abstracts
16.00-17.30Clinical
16.00-16.30The Bone Marrow microenvironment in SCD
L. Silberstein (USA)
16.30-17.00Hemolysis in SCD and its Complications
K. Yazdanbakhsh(USA)
17.00-17.30Selected abstracts
16.00-17.30Cellular Therapy
16.00-16.30Proven and Unproven cell therapies: What have we learned so far?  
F. Lim (Singapore)
16.30-17.00Eye drops of human origin (EDHO): patients, donors and new products
C. Gabriel (Austria)
17.00-17.30Selected abstracts
16.00-17.30All you want to learn about Guidelines
16.00-16.30How to develop international transfusion guidelines 
N. Shehata (Canada)
16.30-17.00Guideline implementation: successes and challenges – UK experience 
S. Allard (United Kingdom)
17.00-17.30Adapting guidelines for global application – how can ISBT help
R. Rama Sharma (India)
16.00-17.30Working Party Session: Red cell terminology 
16.00-16.20What is a “blood group”, and what is an “antigen” – general definitions 
G. Daniels (United Kingdom)
16.20-16.40The new blood group system No. 37 – “KANNO” 
K. Ogasawara (Japan)
16.40-17.00The new blood group system No. 38 - “SID”
M. Olsson (Sweden)
17.00-17.20The (presumably) new blood group system No. 39 – “CTL2”
T. Peyrard (France)
17.20-17.30Discussion
16.00-17.30Working Party Session: Blood supply management
16.00-16.30Results of Survey on Best Practice for "Reducing out-dating of platelets and Red cell'
E. Jansen (The Netherlands)
16.30-17.00Approach to reducing/minimizing expiry of blood and components in Australia
G. Wilkie (Australia)
17.00-17.30TBA
17.45-18.45Poster Session
19.00-23.00Congress party
08.30-10.00Jean Julliard Prize session
10.30-12.00Presidential Award Session
12.00-13.30Lunch and satellite symposia

 

 

13.30-15.00Donors and Donation
13.30-14.00Strategies and theories to attract and retain blood donors: Is it just a warm glow
E. Ferguson (United Kingdom)
14.00-15.00Selected abstracts
13.30-15.00Blood products
11.30-12.00Use of whole blood as the routine transfusion product in Africa
K. Maitland (United Kingdom)
13.30-15.00Immunology
13.30-15.00Selected abstracts
13.30-15.00Blood safety
13:30-14:00Genomics and big data in blood safety
H. Ullum (Denmark)
13.30-15.00Working Party Session: Platelet immunobiology
 CD36, an important alloantigen on platelets and leukocytes 
M. Ando (Japan)
 Platelet and leukocytes in TRALI - players or bystanders?
J. Semple (Sweden)
 Diagnosing autoimmune responses to platelets and leukocytes: state of the art
U. Sachs (Germany)
15.00-15.30Break, exhibition and poster display
15.30-17.00Plenary Session III: Arthropod transmitted infections: New Strategies for eradication
15.30-16.00The Monkeybar Project: identifying environmental factors for emerging zoonotic malaria 
K. Fornace (United Kingdom)
16.00-16.30Engineering malaria resistance in mosquitoes: Gene Driving
A. Crisanti (United Kingdom)
16.30-17.00Eliminating Arboviruses by modifying the insects gut microbiome
TBA
17.00-17.15Closing ceremony